Transmedics Group Stock

Transmedics Group EPS

The Earnings per Share (EPS) of Transmedics Group (TMDX) as of Aug 4, 2026 is 4.65 USD. In the previous year, Earnings per Share (EPS) was 1.01 USD — a change of 361.63% (higher).

EPS

4.65USD

YoY

361.63%

Last updated:

Earnings per Share (EPS) of Transmedics Group is 2026 4.65 USD. Earnings per Share (EPS) of Transmedics Group was 2025 1.01 USD. It decreases by 361.63% higher compared to the previous year.
Access this data via the Eulerpool API

Transmedics Group Stock analysis

What does Transmedics Group do? Transmedics Group Inc is a company dedicated to the development and manufacturing of medical devices for organ transplantation. The company was founded in 1998 and is headquartered in Andover, Massachusetts, USA. Transmedics' business model is based on offering a unique and innovative technology for organ preservation during transport from donor to recipient. The patented Organ Care System (OCS) platform includes a range of state-of-the-art medical devices specifically designed for organ transport. Transmedics' Organ Care System includes three main devices: OCS Heart, OCS Lung, and OCS Liver. Each device is tailored for organ preparation and transport, providing individualized support based on the specific requirements of each organ and different transfer protocols. The OCS technology uses hypothermic (cold) perfusion to preserve the organ during transport. By continuously monitoring and supporting the organ's physiological functions, the OCS system can improve the survival rate of donor organs while reducing the time spent outside the body. Transmedics also offers comprehensive services, including the availability of OCS devices and qualified personnel to provide support throughout the transplantation process. Transmedics' customers include leading transplant centers and hospitals worldwide. The company works closely with these customers to ensure that its OCS devices meet the specific requirements of each transplantation program and help them achieve more successful transplantations. Transmedics' history is marked by a passion for improving transplantation medicine and saving lives through the provision of advanced technologies and solutions. The company has made significant progress in recent years and has experienced strong growth in all areas. Transmedics has also received a number of awards and recognition for its commitment to improving transplantation medicine. For example, in 2020, the company received the Red Herring Top 100 Global Award and was recognized for the seventh consecutive year as one of the fastest-growing companies by Deloitte. Overall, Transmedics is a leading provider of innovative medical devices for transplantation medicine. Through its organic technology and comprehensive service, the company supports transplant centers and hospitals worldwide in performing more successful transplantations and saving patients' lives. Transmedics Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transmedics Group stock

Earnings per Share (EPS) of Transmedics Group is 4.65 USD in 2026.

Earnings per Share (EPS) of Transmedics Group changed from 1.01 USD to 4.65 USD, representing a 361.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Transmedics Group since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

Income Statement — Transmedics Group

All Key Metrics — Transmedics Group